Artemis Medicare Services Limi Overview
Artemis Medicare Services is a promoter-controlled, mid-sized Indian private hospital operator anchored by a single, high-acuity JCI- and NABH-accredited quaternary-care campus in Gurugram, Delhi-NCR. The flagship generates the overwhelming majority of group revenue and commands one of the highest average revenues per occupied bed (ARPOB) in the NCR market — INR 82,435 in FY26 — driven by a complex case mix (oncology, cardiac sciences, neurosciences, orthopaedics, transplants, robotics) and a large medical-value-travel franchise that contributed roughly 31% of Gurugram revenue in FY26. Backed by the Apollo Tyres promoter family and a World Bank Group (IFC) equity investment, the company is transitioning from a one-hospital story to a multi-site platform: an asset-light operations-and-management model in Raipur (opened July 2026), a 650+ bed managed hospital in South Delhi (VIMHANS, targeted FY29), Mauritius O&M contracts, and brownfield Gurugram towers — with a stated ambition to roughly triple capacity to 2,000+ beds by 2029.
What the company does
AMSL owns and operates multi-specialty tertiary and quaternary care hospitals and allied care formats. Its business is the delivery of in-patient (IP) and out-patient (OP) clinical services — surgery, critical care, diagnostics, interventional procedures, transplants and day-care — billed per episode of care. The company reports a single operating segment, "Healthcare Services," in its audited results (FY26 iXBRL filing).
The company's own description in recent filings and presentations positions Artemis Hospitals as a healthcare venture launched by the Apollo Tyres Group promoters, operating a super-speciality hospital in Gurugram (described in the Q3 FY26 presentation as a ~700-bed facility) and expanding toward ~2,000 beds. Its earlier descriptions (IFC investment press release, April–May 2024) cite 713 beds across the Delhi-NCR footprint, including the 541-bed JCI/NABH-accredited Gurugram hospital, five hospitals under the Artemis Lite and Daffodils brands, and seven Artemis Cardiac Care centres run with Philips.
Business and revenue model
| Revenue model element | Description | Evidence |
|---|---|---|
| Owned-hospital services (core) | Fee-for-service billing at the owned Gurugram campus; revenue = occupied bed-days × ARPOB plus OP revenue | Gurugram contributed INR 1,060 Cr standalone of INR 1,081 Cr consolidated revenue in FY26 (FY26 results) |
| Operations & Management (O&M) / Medical Services Agreements (MSA) | Asset-light (or asset-lighter) contracts where a third party owns land/building and Artemis runs clinical operations under its brand: Raipur (Artemis Shanti), VIMHANS South Delhi, Mauritius (Curepipe, Cascavelle) | Raipur O&M/MSA (intimated 14 Nov 2024); VIMHANS MSA (20 Feb 2026); Mauritius O&M (FY24) |
| Satellite / secondary care formats | Artemis Lite (30–40 bed neighbourhood multi-specialty hospitals), Daffodils by Artemis (mother-and-child) | CARE rationale Aug 2023 and Aug 2025 |
| Cardiac network JV | Artemis Cardiac Care Pvt Ltd (65% AMSL; Philips partner) operating cardiac centres in Tier 2/3 locations | BRSR FY26; IFC release 2024 |
| Medical value travel (MVT) | International patients from 52 countries (Middle East, Africa, CIS); 31.3% of Gurugram net revenue in FY26 | Q3 FY26 commentary; Q4 FY26 release |
There is no meaningful product, subscription or licensing revenue; the mix is essentially 100% service revenue. "Other income" (treasury income on unutilised IFC proceeds) was a material contributor to pre-tax profit in FY25–FY26 and has been declining as funds are deployed into capex (Q3 FY26 and Q1 FY27 presentations).
Customer types and payor mix (Gurugram)
| Payor category | Q4 FY26 share of revenue (%) | Q1 FY27 share of revenue (%) | Source |
|---|---|---|---|
| International patients | 31 | 27 | Q4 FY26 call notes; Q1 FY27 presentation |
| Insured (TPA/corporate insurance) | 31 | 33 | Same |
| Domestic cash | 22 | 23 | Same |
| Government schemes (CGHS/ECHS/PSU etc.) | ~16 (implied) | 17 | Same (Q4 government share is a residual, derived) |
Value-chain position and end-markets
Artemis sits at the high-acuity end of the provider value chain (tertiary/quaternary care), competing for complex referrals (oncology, neurosurgery, cardiac surgery, solid-organ and heart-lung transplant, robotic surgery) rather than primary care volume. Its end-markets are: (a) affluent and insured patients in Gurugram/South Delhi; (b) government-scheme patients (a lower-yield but volume-stabilising cohort); (c) inbound medical travellers; and, newly, (d) Central India (Chhattisgarh) via Raipur.
Independent characterisation
Analytically, AMSL is best understood as a single-asset, high-ARPOB, MVT-heavy hospital that is now spending its balance-sheet capacity (IFC money plus a pending INR 700 Cr raise) to become a three-to-four-asset network. The core asset is mature-to-maturing (occupancy 61–66%, ARPOB growing 7–10% a year), so the next leg of earnings growth depends on execution of new capacity that carries gestation losses (management guided INR 18–20 Cr of losses over the first 15–18 months at Raipur). The model also leans increasingly on O&M/MSA structures, which lower capital intensity but introduce counterparty, contract-tenure and economic-sharing risks that are less transparent than owned-hospital economics.
Strategy
Stated strategic themes (paraphrased from FY26 calls, presentations and releases)
-
Scale capacity roughly 2.5–3x. Move from ~800 beds to 2,000–2,300 beds by 2029 through a blend of brownfield (Gurugram towers and FAR uplift), greenfield/managed (VIMHANS South Delhi), and O&M/MSA hospitals (Raipur, Mauritius). Earlier presentations cited ~2,000 beds by 2028; the target year has since been stated as 2029.
-
Deepen high-acuity clinical programmes. Build centres of excellence in transplants (including heart-lung), robotics, neurosciences, oncology and critical care to sustain NCR-leading ARPOB.
-
Sustain medical value travel at ~30% of flagship revenue while broadening domestic insured volumes.
-
Asset-light geographic expansion into under-served Tier 2 markets (Raipur first), with VIMHANS providing a second NCR anchor.
-
Disciplined pricing and mix: FY27 budget assumed ~15% top-line growth, ~15% price hikes and 7–8% annual ARPOB growth.
-
Capital structure: fund growth from a mix of equity (INR 700 Cr raise; promoters not participating), debt and internal accruals.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Raipur O&M/MSA | Intimated 14 Nov 2024 | 300+ bed Artemis Shanti Hospital; >50 specialities; 11 CoEs | Operational from 9 Jul 2026; gestation losses INR 18–20 Cr over 15–18 months guided |
| ABTP physiotherapy partnership | FY25 | Technology-enabled rehab | Operational |
| Gurugram third tower | FY26 | Built capacity ~700 beds | Operational (544 beds open) |
| Platinum green building certification | Q3 FY26 | Entitles 15% FAR uplift, enabling 100+ additional beds | Achieved |
| New departments: Robotics, Heart & Lung, Geriatrics | FY26 | Higher manpower cost, temporary margin impact | Operational |
| Heart & Lung Transplant Centre / KIMS collaboration | 2025–2026 | Transplant programme collaboration with KIMS Hospitals, Hyderabad | Operational |
| INR 700 Cr fundraise | Board 2 Feb 2026; shareholders 20 Jul 2026 | QIP/preferential/private placement; equity, convertibles, NCDs, warrants permitted | Approved; execution/pricing not announced as of cut-off |
| VIMHANS Artemis Hospital MSA | 20 Feb 2026 | 15-year MSA; 650+ beds; capex INR 500–520 Cr (~INR 75–80 lakh per bed); interest-free advance tied to construction milestones | Pre-construction; construction expected to begin Apr–May 2026; ~450 beds by FY29 |
| Three-year capex plan | Q1 FY27 call (Aug 2026) | INR 800 Cr covering Gurugram (Tower IV, 200+ beds for paediatrics/obstetrics), Raipur and VIMHANS | Announced |
| Additional Gurugram beds | Q4 FY26 call | 100 beds ready; open 50 when occupancy reaches ~70%, then another 50; expected H2 FY27 | Pending occupancy trigger |
| Mauritius Cascavelle | FY26–FY27 | Second Mauritius hospital, 110 beds | Announced |
| Investor engagement | Mar–Sep 2026 | Hospitals & Diagnostics Conference (23 Mar), hospital visit (19 Jun), PhillipCapital Market Marvel conference (3 Sep) | Completed |
Medium-term financial targets / guidance
| Item | Guidance | Source |
|---|---|---|
| Bed capacity | 2,000–2,300 by 2029 | Q3/Q4 FY26 calls |
| FY27 top-line growth (budget) | ~15% | Q4 FY26 call analysis |
| ARPOB growth | 7–8% p.a. | Q4 FY26 call analysis |
| International growth FY27 | "Higher double digits" | Q4 FY26 call notes (ValuePickr summary) |
| Raipur losses | INR 18–20 Cr over first 15–18 months | Q4 FY26 / Q1 FY27 commentary |
| Absolute EBITDA | Continued expansion in FY27 led by Gurugram occupancy and new beds | Q4 FY26 call notes |
| Capex | INR 800 Cr over three years | Q1 FY27 commentary |
| VIMHANS capex | Phase 1 ~INR 350 Cr for 450 beds; Phase 2 ~INR 150 Cr for 200 beds | Q4 FY26 call notes |
Products & Services
Because AMSL is a hospital operator, its "products" are care formats, facilities and clinical service lines. The catalog below is organised by format, then by clinical programme.
Facilities and care formats
| Offering | Description & capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Artemis Hospital, Gurugram | Flagship multi-specialty quaternary care campus, Sector 51; JCI & NABH accredited; ~700 beds built across three towers, ~544 operational (Q3 FY26); 100 additional beds ready, to be opened in two lots of 50 once occupancy reaches ~70% | Affluent/insured NCR patients, international patients, government-scheme patients | Opened 2007; third tower FY26; Tower IV (200+ beds, paediatrics/obstetrics) planned | Fee-for-service; FY26 ARPOB INR 82,435 |
| Artemis Shanti Hospital, Raipur | 300+ bed multi-specialty tertiary care hospital in Devendra Nagar, Raipur; >50 specialities, 11 Centres of Excellence; cardiology, oncology, neurosciences, orthopaedics, nephrology, critical care, emergency medicine | Chhattisgarh and Central India patients who would otherwise travel to metros | OPD from 9 Jul 2026; OTs/cath labs from 27 Jul 2026; phased bed opening (reported first phase ~150–200 beds) | O&M/MSA; fee-for-service to patients |
| VIMHANS Artemis Hospital, South Delhi | 650+ bed multi-specialty hospital to be developed on a 3.5-acre site in Nehru Nagar; ~7 lakh sq ft built-up; CoEs in neurosciences, cardiac sciences, oncology, organ transplantation, critical care and robotic surgery | South Delhi high-ARPOB micro-market | MSA signed 20 Feb 2026; ~450 beds by FY29 (Phase 1), 650+ in Phase 2 | 15-year MSA; land and building owned by VIMHANS society |
| Artemis Lite | 30–40 bed neighbourhood multi-specialty hospitals for secondary/tertiary care | Local catchments in South Delhi and New Gurugram | First centre 2023 (South Delhi); New Gurugram unit opened subsequently | Fee-for-service; asset-light |
| Daffodils by Artemis | Mother-and-child care centres (obstetrics, gynaecology, paediatrics, neonatal) | Women and children in Gurugram, South Delhi, Jaipur | Gurugram first; Jaipur and South Delhi added 2023 | Fee-for-service; asset-light |
| Artemis Cardiac Care | Cardiac care centres in Tier 2/3 cities via JV with Philips (seven centres cited in 2024) | Cardiac patients outside metros | JV incorporated Jan 2019 | Fee-for-service |
| Artemis Curepipe Hospital, Mauritius | ~80-bed hospital operated under O&M agreement | Mauritian patients | Opened FY24 | Management fee (terms not disclosed) |
| Artemis Cascavelle Hospital, Mauritius | 110-bed facility, second Mauritius hospital | Mauritian patients | Announced for FY26 | Management fee (terms not disclosed) |
Clinical programmes and centres of excellence (Gurugram unless stated)
| Programme | Description | Latest development | Source |
|---|---|---|---|
| Oncology | Medical, surgical and radiation oncology; high-acuity case mix contributor | Core specialty | CARE rationales; company profile |
| Cardiac sciences | Interventional cardiology, cardiac surgery | Heart & Lung Transplant Centre inaugurated; heart-lung transplant programme in collaboration with KIMS Hospitals, Hyderabad | Medical Dialogues; ScanX (Jul 2026) |
| Neurosciences | Neurology, neurosurgery, interventional neuro | Core specialty | Company profile |
| Orthopaedics & joint replacement | Including robotic joint replacement | Core specialty | Company profile |
| Organ transplantation | Kidney, liver; heart-lung added | Heart-lung programme new | Same |
| Robotic surgery | New department added FY26 (manpower cost driver) | Added FY26 | Q3 FY26 presentation |
| Geriatrics | New department added FY26 | Added FY26 | Q3 FY26 presentation |
| Critical care | Highlighted on Q4 FY26 call as a success story | Ongoing | Q4 FY26 call |
| Nephrology, gastroenterology, minimally invasive surgery | Established specialties; no single specialty historically >13% of revenue | Ongoing | CARE rationale 2017 |
| Physiotherapy & sports rehab | Technology-enabled physiotherapy through partnership with Abhinav Bindra Targeting Performance (ABTP) | FY25 | FY25 Directors' Report |
| OPTIC clinic | First "OPTIC Clinic" launched (scope not detailed in sources reviewed) | 2,026 | Medical Dialogues link reference |
| Medical value travel desk | International patient services for 52 countries; Middle East, Africa, CIS | FY26 overseas revenue INR 322.68 Cr, +26.9% | Q4 FY26 release |
| Digital / patient-flow technology | Technology deployed to improve patient flow and operational efficiency (details not disclosed) | Q3 FY26 call | Q3 FY26 transcript |
Pricing: management indicated that the FY27 budget assumed price increases of about 15% across domestic and international patients and ARPOB growth of 7–8% annually (Q4 FY26 call analysis, Arthneeti). Procedure-level tariffs are not publicly disclosed.
Financial Narrative
All figures consolidated, INR Cr, fiscal years ending 31 March. Primary anchors: FY26 audited results (8 May 2026) and company press releases. FY22–FY25 line items are taken from StockAnalysis (S&P-sourced, INR millions converted to crore) unless stated, cross-checked against Fyers/Screener totals.
Income statement
Notes: FY26 PAT INR 103.72 Cr (company: +26.2%); PAT attributable to owners INR 103.62 Cr; reported PBT INR 139.18 Cr after an exceptional charge of INR 3.07 Cr (FY26 iXBRL: PBT before exceptional INR 14,225.22 lakh, PBT INR 13,917.78 lakh). FY25 PBT INR 107.67 Cr (Fyers). FY22–FY24 PAT derived from StockAnalysis net margins (5.73%, 5.23%, 5.59%) applied to revenue; FY24 PAT of ~INR 49 Cr is corroborated by Venture Intelligence. "Gross profit" is the aggregator's construct (revenue less cost of revenue including clinical costs) and is not a company-reported metric.
EBITDA (company-reported, INR Cr)
Source: FY26 EBITDA INR 21,801 lakh, +18.0% (Q4 FY26 release); FY25 derived from growth rate.
Per-share data
Notes: EPS shown is a derived approximation; reported basic and diluted EPS differ because of weighted-average share counts and, until conversion, the dilutive IFC CCDs. Reported diluted EPS data points: Q1 FY26 INR 1.54; 9M FY26 INR 4.66 (+21.0%); Q3 FY26 INR 1.41; Q1 FY27 INR 1.98 (+46.7%).
Balance sheet (INR Cr, 31 March)
Source: StockAnalysis balance sheet (INR millions converted). Goodwill & intangibles: not separately disclosed in sources retrieved; hospital operators of this type typically carry minimal goodwill, and no acquisition-related goodwill was identified. Discrepancy note: Arihant Capital's standalone balance sheet shows FY25 total debt of INR 280.5 Cr (secured INR 236.0 Cr plus unsecured INR 44.5 Cr) and cash and bank of INR 393.3 Cr — the large cash figure reflects bank deposits from the IFC proceeds classified outside "cash and equivalents" in the StockAnalysis presentation. On a gross-liquidity basis (including deposits), AMSL was likely net-cash at end-FY25; on the narrow cash definition it shows net debt. Readers should treat "net debt" above as an upper bound.
Cash flow (INR Cr)
Notes and discrepancies: (1) Stockopedia shows FY25 OCF of INR 145.6 Cr versus StockAnalysis INR 155.7 Cr. (3) FY25 debt issuance of INR 350.8 Cr includes the IFC CCDs (INR 330 Cr), which were debt-classified until conversion. Dividends paid: approx. INR 6.2 Cr per year at INR 0.45 on ~137.6 M shares (derived); buybacks: none.
Ratios (derived from tables above; period-end balances)
Additional ratios: Net debt/EBITDA FY25 1.35x and FY26 1.05x (derived; narrow-cash basis). ROIC: not computed due to absence of a reliable tax-adjusted invested-capital series; Screener cites ROCE of 14.9% and ROE of 12.9% (Oct 2026 snapshot) and average 3-year ROE of 11.7%. Cash conversion cycle series is from Screener's standalone data (the last five values in its series are mapped to FY22–FY26; FY26 shown as 37 on one Screener snapshot — minor discrepancy). Fyers shows debt-to-equity of 0.26.
Quarterly trajectory (consolidated, INR Cr)
Sources: Q1 FY27 release (revenue INR 287.32 Cr, EBITDA INR 61.82 Cr, PAT INR 31.44 Cr total / INR 31.31 Cr attributable); Q4 FY26 release (revenue INR 279.23 Cr, EBITDA INR 59.38 Cr, PAT INR 30.28 Cr); Q3 FY26 (revenue INR 272 Cr, EBITDA INR 52 Cr, PAT INR 22.3 Cr); Q1 FY26 from Fyers quarterly series (revenue INR 254.96 Cr; PAT INR 21.28 Cr); Q1 FY26 EBITDA derived from Q1 FY27 growth of 27.9%; Q2 FY26 revenue/EBITDA from Fyers rounded series; Q2 FY26 PAT derived as FY26 PAT less other quarters. Discrepancy: AlphaStreet reported Q1 FY26 revenue as ~INR 250 Cr and INDmoney shows total-income figures (INR 292.70 Cr for Q1 FY27), which include other income.
Commentary on trends, inflections and drivers
Revenue. Growth decelerated sharply from the post-COVID rebound years (36% in FY22, 33% in FY23) to 19% in FY24 and only 6.6% in FY25, before reaccelerating to 15.4% in FY26. The FY25 trough coincided with capacity constraints at the flagship ahead of the third tower and payor-mix noise; the FY26 rebound was driven by ARPOB (+7.8% to INR 82,435 at Gurugram) and a 26.9% jump in overseas-patient revenue. Q1 FY27 growth of 12.7% was achieved despite a sequential softening in international mix (27% vs 31% in Q4 FY26), attributed in part to West Asia geopolitical disruption.
Profitability. Operating margin expanded roughly 470 bps over four years (8.4% to 13.1%), and Q1 FY27 delivered the highest operating margin (ex-other income) in at least eight quarters at 19.6% on an EBITDA-like basis (MarketsMojo). Margin expansion stems from operating leverage on a largely fixed cost base, ARPOB-led pricing and a richer case mix, partially offset in FY26 by manpower additions for robotics, heart-lung and geriatrics. A critical quality-of-earnings point: other income (mainly treasury income on IFC funds) was INR 33.0 Cr in FY25 and INR 29.9 Cr in FY26 (total income minus revenue from ops, derived) — roughly 31% and 21% of PBT respectively — and is declining as funds are deployed (Q1 FY27 other income ~INR 5.4 Cr). Core operating profit, not treasury income, must now carry earnings growth.
Balance sheet. The IFC raise transformed the capital structure in FY25: equity nearly doubled on conversion (INR 448 Cr to INR 838 Cr between FY24 and FY25 on the aggregator's presentation, with share count rising in FY26), debt/equity fell from 0.71x to 0.28x by FY26, and interest coverage improved to 5.8x. Finance costs fell to INR 6.46 Cr in Q1 FY27 from INR 7.38 Cr a year earlier.
Cash flow. FCF has been positive but thin since FY24 (INR 27–63 Cr), as the company continuously reinvests in towers and equipment. The announced INR 800 Cr three-year capex plan (Gurugram Tower IV, Raipur, VIMHANS) will far exceed internal accruals of roughly INR 130–160 Cr per year of OCF, explaining the INR 700 Cr fundraise authorisation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Healthcare Services revenue from operations (INR Cr) | 878.6 | 936.9 | 1,081.2 |
YoY growth (%) | 19.1 | 6.6 | 15.4 |
Share of total revenue (%) | 100 | 100 | 100 |
Revenue by Segment
| Metric | FY2025 | FY2026 |
|---|---|---|
Standalone AMSL revenue from operations (INR Cr) | 913.3 | 1,060.5 |
Subsidiary and consolidation adjustments, derived (INR Cr) | 23.6 | 20.8 |
Consolidated revenue from operations (INR Cr) | 936.9 | 1,081.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFormat / Unit Details
| Format / unit | What it contains | FY2025 revenue (INR Cr) | Notes / source |
|---|---|---|---|
Artemis Hospital, Gurugram (flagship) | Quaternary/tertiary care, JCI and NABH accredited; ~544 operational beds | Not separately disclosed for full year; FY26 overseas revenue INR 322.68 Cr at 31.3% implies Gurugram net revenue of roughly INR 1,031 Cr (derived) | Q4 FY26 release |
Artemis Daffodil | Mother-and-child / women's care units (Gurugram, Jaipur, South Delhi) | 21.10 | CARE rationale Aug 2025 |
Artemis Lite | 30–40 bed neighbourhood multi-specialty hospitals (South Delhi, New Gurugram) | 19.60 | CARE rationale Aug 2025 |
Artemis Cardiac Care Pvt Ltd | Cardiac centres in Tier 2/3 cities with Philips (7 centres per 2024 release) | Subsidiary revenue not separately disclosed; subsidiary Q1 FY27 net profit INR 0.38 Cr; total assets INR 22.60 Cr | Q1 FY27 results notes |
Mauritius O&M | Artemis Curepipe (~80 beds), Artemis Cascavelle (110 beds) | — | Presentations |
Raipur (Artemis Shanti) | 300+ bed super-speciality hospital under O&M/MSA | Nil (commenced Jul 2026) | Reg. 30 disclosure |
VIMHANS Artemis Hospital | 650+ bed hospital under 15-year MSA | Nil (targeted FY29) | Reg. 30 disclosure |
Artemis Solace | Named as a diversified care model by AlphaStreet; scope not detailed in primary sources reviewed | — | AlphaStreet, Q1 FY26 note |
“—” = not publicly disclosed.
Segment Revenue
| Metric | Q4 FY25 | Q4 FY26 | Q1 FY26 (derived) | Q1 FY27 |
|---|---|---|---|---|
Revenue from operations | 225.1 (derived) | 267.5 | 241.3 | 278.5 |
EBITDA | 48.1 | 58.0 | 49.5 | 61.6 |
PAT | 26.2 (derived) | 31.4 | 24.9 | 33.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 554.8 | 737.4 | 878.6 | 936.9 | 1,081.2 |
Total income incl. other income (INR Cr) | 558.7 | 744.8 | 885.9 | 969.9 | 1,111.1 |
Gross profit, aggregator definition (INR Cr) | 91.9 | 138.1 | 177.6 | 197.7 | 237.7 |
Operating income / EBIT before other income (INR Cr) | 46.5 | 63.9 | 93.5 | 108.1 | 142.1 |
Interest expense (INR Cr) | 9.4 | 17.3 | 27.8 | 28.5 | 24.5 |
Pre-tax income excl. unusual items (INR Cr) | 37.7 | 49.5 | 68.2 | 105.5 | 141.0 |
Net income / PAT (INR Cr) | 31.8 | 38.6 | 49.1 | 82.6 | 103.7 |
Revenue growth (%) | 35.9 | 32.9 | 19.1 | 6.6 | 15.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Consolidated EBITDA (INR Cr) | 184.8 | 218.0 |
EBITDA margin (%) | 19.7 | 20.2 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin, aggregator basis (%) | 16.6 | 18.7 | 20.2 | 21.1 | 22.0 |
Operating margin (%) | 8.4 | 8.7 | 10.6 | 11.5 | 13.1 |
Net margin on revenue from ops (%) | 5.7 | 5.2 | 5.6 | 8.8 | 9.6 |
Share Count (millions) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares outstanding, period-end (millions) | 132.4 | 134.1 | 135.9 | 137.6 | 158.3 |
EPS approx., PAT / period-end shares (INR) | 2.40 | 2.88 | 3.61 | 6.00 | 6.55 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Revenue CAGR FY2022–FY2026 (4-year) | 18.2% | Derived from INR 554.8 Cr to INR 1,081.2 Cr |
Revenue CAGR FY2023–FY2026 (3-year) | 13.6% | Derived |
PAT CAGR FY2022–FY2026 | 34.4% | Derived from INR 31.8 Cr to INR 103.7 Cr |
Screener: 5-year profit CAGR | 32.5% | Screener, Oct 2026 |
Last verified price | INR ~311 (NSE) | 12 Oct 2026, Kotak Neo / Tickertape |
Market cap | ~INR 4,958 Cr | 12 Oct 2026 |
52-week high / low | INR 378.80 / INR 203.35 | Kotak Neo, 12 Oct 2026 (Anand Rathi in mid-Sep showed INR 361.50 / INR 202.85 — discrepancy) |
1-year return | ~30.0% | Kotak Neo, 12 Oct 2026 |
3-year return | ~150% | Anand Rathi, Sep 2026 |
Recent price points | INR 274.6 (29 May 2026); INR 259.2 (18 Jun 2026); INR 298.5 (31 Jul 2026); INR 316.9 (10 Aug 2026); INR 326.1 (22 Aug 2026); INR 337.5 (15 Sep 2026); INR 311 (12 Oct 2026) | Various aggregators |
Metric | May2026 | Jun2026 |
Share price, sampled close (INR) | 274.6 | 259.2 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 709.7 | 905.0 | 971.5 | 1,357.4 | 1,428.7 |
Cash and equivalents (INR Cr) | 15.7 | 22.9 | 14.6 | 41.6 | 33.4 |
Cash plus short-term investments (INR Cr) | 27.7 | 50.9 | 14.6 | 41.6 | 33.4 |
Current portion of long-term debt (INR Cr) | 22.3 | 27.9 | 25.8 | 36.3 | 36.9 |
Long-term debt (INR Cr) | 161.3 | 213.6 | 227.7 | 209.5 | 190.0 |
Total debt incl. leases (INR Cr) | 201.2 | 285.9 | 320.3 | 290.3 | 261.6 |
Net debt (INR Cr) | 173.5 | 234.9 | 305.7 | 248.7 | 228.2 |
Total equity (INR Cr) | 359.4 | 403.1 | 448.4 | 837.7 | 934.7 |
Total current assets (INR Cr) | 127.0 | 170.4 | 180.1 | 535.1 | 366.8 |
Total current liabilities (INR Cr) | 138.2 | 205.8 | 184.6 | 216.1 | 210.8 |
Working capital, derived (INR Cr) | -11.2 | -35.4 | -4.5 | 319.0 | 156.0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 59.5 | 127.2 | 108.9 | 155.7 | 131.9 |
Capital expenditure, derived (INR Cr) | 108.9 | 146.5 | 72.6 | 93.1 | 104.9 |
Free cash flow (INR Cr) | -49.4 | -19.3 | 36.3 | 62.6 | 27.0 |
Investing cash flow (INR Cr) | -107.2 | -158.2 | -88.1 | -393.2 | -90.0 |
Financing cash flow (INR Cr) | 44.2 | 38.2 | -29.0 | 264.5 | -50.1 |
Long-term debt issued (INR Cr) | 79.1 | 82.8 | 45.3 | 350.8 | 64.2 |
Long-term debt repaid (INR Cr) | 24.6 | 27.5 | 37.2 | 40.3 | 80.9 |
Cash interest paid (INR Cr) | 11.1 | 20.1 | 33.0 | 31.1 | 27.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, period-end equity (%) | 8.8 | 9.6 | 11.0 | 9.9 | 11.1 |
ROA, period-end assets (%) | 4.5 | 4.3 | 5.1 | 6.1 | 7.3 |
Current ratio (x) | 0.92 | 0.83 | 0.98 | 2.48 | 1.74 |
Debt to equity (x) | 0.56 | 0.71 | 0.71 | 0.35 | 0.28 |
Interest coverage, EBIT / interest (x) | 4.97 | 3.70 | 3.37 | 3.79 | 5.81 |
Asset turnover, revenue / assets (x) | 0.78 | 0.81 | 0.90 | 0.69 | 0.76 |
Cash conversion cycle (days) | 50 | 48 | 47 | 43 | 36 |
Income Statement
| Metric | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 255.0 | 275.0 | 272.0 | 279.2 | 287.3 |
EBITDA (INR Cr) | 48.3 | 58.0 | 52.0 | 59.4 | 61.8 |
PAT (INR Cr) | 21.3 | 29.8 | 22.3 | 30.3 | 31.3 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Overseas-patient revenue, Gurugram (INR Cr) | 254.3 | 322.7 |
Domestic revenue, consolidated less overseas, derived (INR Cr) | 682.6 | 758.6 |
Overseas share of Gurugram net revenue (%) | 28.0 | 31.3 |
Overseas revenue growth (%) | 0 | 26.9 |
Revenue by Region (%) and Region Margins & Growth (%)
| Metric | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|
Overseas share of revenue (%) | 34.0 | 30.8 | 27.5 |
Overseas revenue YoY growth (%) | 34.9 | 13.5 | 8.6 |
Geography Overview
| Geography | Role | Disclosure |
|---|---|---|
India — Delhi-NCR (Gurugram, South Delhi) | Core; flagship, Lite, Daffodils, future VIMHANS | ~95%+ of revenue (derived from entity split) |
India — Rajasthan (Jaipur) | Daffodils unit | — |
India — Chhattisgarh (Raipur) | New tertiary hospital from Jul 2026 | No revenue in FY26 |
India — Tier 2/3 cities | Artemis Cardiac Care centres | Subsidiary revenue small (consolidation residual ~INR 21 Cr FY26) |
Mauritius | O&M of Curepipe and Cascavelle hospitals | — |
International patient source markets | Middle East, Africa, CIS (52 countries) | Country-level split not disclosed |
“—” = not publicly disclosed.
Valuation Multiples
| Multiple | Artemis | Basis |
|---|---|---|
P/E (TTM) | 43.6x | Mcap INR 4,958 Cr / TTM PAT INR 113.7 Cr (FY26 PAT – Q1 FY26 + Q1 FY27) |
EV/EBITDA (TTM) | 22.4x | EV INR 5,186 Cr (mcap + Mar-26 net debt INR 228 Cr) / TTM EBITDA INR 231.5 Cr |
EV/Sales (TTM) | 4.7x | EV / TTM revenue INR 1,113.5 Cr |
P/B | 5.3x | Mcap / Mar-26 equity INR 934.7 Cr (aggregators show 3.2x–5.0x depending on date and book definition) |
Dividend yield | ~0.15% | INR 0.45 / INR 311 |
Dividend History
| Fiscal year | DPS (INR) | Record / ex-date | Status |
|---|---|---|---|
FY2024 | 0.45 | Ex-date 5 Jul 2024 | Verified |
FY2026 | 0.45 | Record date 10 Jul 2026; approved at AGM 31 Jul 2026 | Verified |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
CARE Ratings — long-term bank facilities (INR 427.90 Cr) | CARE A | Stable | Reaffirmed 12 Aug 2025 |
CARE Ratings — long/short-term facilities (INR 45 Cr) | CARE A / CARE A2+ | Stable | Reaffirmed 12 Aug 2025 |
Moody's / S&P / Fitch | Not rated | — | — |
Analyst Conclusions
Management guidance (FY27 and beyond)
Management has framed FY27 around ~15% top-line growth, 7–8% ARPOB growth, continued absolute EBITDA expansion at Gurugram, phased opening of 100 additional Gurugram beds once occupancy approaches 70%, and Raipur gestation losses of INR 18–20 Cr over 15–18 months. Longer term, it targets 2,000–2,300 beds by 2029 backed by an INR 800 Cr three-year capex plan and an INR 700 Cr equity raise. Consensus growth expectations: not publicly disclosed in sources reviewed.
Bull case
-
Core flagship compounding: Gurugram delivered +15.4% revenue and +24.4% EBITDA in Q1 FY27 with occupancy at 65.7%; crossing ~70% unlocks 100 ready beds at minimal incremental capex, extending double-digit growth into FY28.
-
Capacity optionality at low capital intensity: VIMHANS (~INR 75–80 lakh per bed under an MSA) and Raipur (O&M) add roughly 950 beds without full land/building ownership, which could lift ROCE once ramped.
-
Valuation gap: at ~44x TTM earnings and ~22x EV/EBITDA, Artemis trades below most large NCR peers despite comparable ARPOB; successful execution and the equity raise could drive a rerating toward peer multiples.
Bear case
-
Earnings quality and dilution: treasury income (~21% of FY26 PBT) is fading, Raipur losses will weigh on FY27–FY28, and a full INR 700 Cr raise at current prices implies ~14% dilution — EPS growth could lag headline PAT growth.
-
MVT and competitive headwinds: international share has already slid from 34% to 27% in three quarters; peers are adding thousands of NCR beds, potentially capping occupancy and pricing.
-
Execution and governance overhangs: an MSA-heavy pipeline with interest-free advances, a 44.5% promoter pledge, a single-asset earnings base, and an FY29 timeline for VIMHANS leave limited margin for delay.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q2 FY27 results | Likely early-to-mid Nov 2026 (unconfirmed) | First quarter with Raipur losses; Gurugram occupancy vs 70% trigger |
| INR 700 Cr fundraise execution | H2 FY27 (unconfirmed) | Pricing, dilution, investor quality |
| Opening of additional 100 Gurugram beds | H2 FY27 | Occupancy trigger |
| Raipur ramp | Through FY27 | Bed occupancy, breakeven trajectory vs INR 18–20 Cr loss guidance |
| VIMHANS construction progress | FY27–FY29 | Milestones, advances paid |
| International patient trends | Quarterly | Share vs 30% target; West Asia situation |
| CGST SCN outcome | FY27 | Settlement or litigation |
| Board refresh | FY27 | Replacement of independent director(s) |
| CARE rating review | ~Aug 2027 | Possible upgrade/downgrade given capex |
Analyst verdict
Artemis Medicare enters FY27 in the best operating shape of its 19-year history. The Gurugram flagship is delivering record revenue, NCR-leading ARPOB above INR 85,000, and an EBITDA margin that has broken above 20%, while the IFC capital infusion has cut leverage to a debt-to-equity ratio below 0.3x. FY26 PAT grew 26% and Q1 FY27 PAT grew 48% — numbers that compare favourably with the much larger listed hospital chains.
The investment debate, however, has shifted from "is the flagship good?" to "can a one-hospital company become a four-hospital company without diluting returns?" The answer will be determined over the next 24–36 months by three variables: how quickly Raipur fills its beds in a market with entrenched competitors; whether VIMHANS is delivered on its FY29 timeline and on budget; and whether the INR 700 Cr equity raise is priced well enough that per-share value accretes. Meanwhile, the earnings cushion from treasury income is disappearing, and international patient flows — the core of the premium-yield story — have shown that they are sensitive to geopolitical shocks.
On balance, the evidence supports a constructive but execution-dependent view. The core asset justifies a premium franchise multiple, and the current valuation (~44x TTM P/E, ~22x EV/EBITDA) embeds a discount to large peers that reflects scale and concentration risk rather than core quality. Upside requires Gurugram occupancy to break 70% and Raipur losses to stay within guidance; downside scenarios centre on slower MVT, a heavily dilutive raise, or construction slippage at VIMHANS. Investors should treat the next four quarterly prints — particularly occupancy, Raipur losses and the fundraise terms — as the decisive evidence on whether Artemis can translate its high-quality flagship into a scaled, returns-accretive platform.
Source list (primary and secondary references used)
| Source | Type | Used for |
|---|---|---|
| NSE iXBRL integrated filings — FY26 audited results (8 May 2026); Q2 FY26 results (11 Nov 2025) | Primary filing | Revenue, PBT, PAT, segment, subsidiary |
| Q3 & 9M FY26 earnings presentation (2 Feb 2026) and call transcript (3 Feb 2026, filed 9 Feb 2026) | Primary | ARPOB, MVT, capacity, CFO name |
| Reg. 30 disclosure — VIMHANS MSA (20 Feb 2026) | Primary | VIMHANS terms |
| Reg. 30 disclosure — auditor re-appointment (31 Jul 2026) | Primary | Auditor |
| Reg. 30 disclosure — SMP appointment (18 Sep 2025) | Primary | Management |
| Company press releases via Indian Pharma Post / Equitybulls (Q4 FY26, Q1 FY27, VIMHANS) | Primary (reproduced) | KPIs, quotes |
| IFC project disclosure 49344 | Primary (counterparty) | IFC investment |
| CARE Ratings press releases (2015–2025) | Rating agency | Ratings, history, format revenue |
| Business Standard (ICRA bed estimates) | Media | Industry context |
| ScanX, Sahi, MultiBagg, MarketsMojo, Medical Dialogues, AlphaStreet | Media / aggregators | Newsflow, Raipur, fundraise |
| StockAnalysis, Screener, Fyers, Kotak Neo, Tickertape, Anand Rathi, Angel One, IIFL, Emkay, Arihant, Stockopedia, Simply Wall St, Pocketful, Voguestock | Aggregators | 5-year financials, market data, shareholding, compensation |
| PTL Enterprises and Artemis Global Life Sciences filings (2015–2019) | Primary (historic) | Corporate history |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (latest available) | Source |
|---|---|---|---|---|---|
Dr. Devlina Chakravarty | Managing Director (Executive Director) | Joined as CEO Jan 2014; MD since 2 Feb 2015 | Medical doctor (MD, DNB, DMRD — radiology); long-serving operator of the flagship | — | Simply Wall St |
Sanjiv Kumar Kothari | Chief Financial Officer | — | — | — | Q3 FY26 transcript |
Poonam Makkar | Company Secretary & Compliance Officer (KMP) | Since 9 Nov 2022 | Member, Institute of Company Secretaries of India | ~INR 0.42 Cr (S&P-sourced data) | Board outcome Nov 2022; Simply Wall St |
Rudra Narayan Acharjee | Head – Investor Relations, M&A and Organisation Growth Strategy (SMP) | Since 18 Sep 2025 | Not detailed in sources reviewed | — | Reg. 30 disclosure |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Notes | Source |
|---|---|---|---|
Onkar S. Kanwar | Chairman (Non-Executive, Promoter) | Chairman of Apollo Tyres Ltd | Company releases 2024–2026 |
Neeraj Kanwar | Non-Executive Director (Promoter group) | Vice Chairman & MD of Apollo Tyres; retired by rotation and re-appointed at 21st AGM (2025) | FY25 Directors' Report |
Shalini Kanwar Chand | Non-Executive Director (Promoter group) | — | MarketsMojo management list (Mar 2023) |
Dr. Devlina Chakravarty | Managing Director | Executive | Same |
Deepa Gopalan Wadhwa | Independent Director | Former Indian diplomat (Ambassador) — background per public record | Same |
Sunil Tandon | Independent Director | — | Same |
S. Narayan | Independent Director | Former Finance Secretary, Government of India — per public record | Same |
Dr. Nirmal Kumar Ganguly | Independent Director | Former Director-General, ICMR — per public record | Same |
Dr. Sanjaya Baru | Independent Director | Economist and former media adviser to the Prime Minister — per public record | Same |
Sanjib Sen | Independent Director (ceased) | Second term 3 Aug 2023 – 2 Aug 2026; ceased on completion of tenure | FY24 Directors' Report; Reg. 30 disclosure Aug 2026 |
Major Shareholders
| Holder | Stake (%) | As of | Source |
|---|---|---|---|
Constructive Finance Private Limited (promoter holding company) | 58.38 | Jun 2026 | MarketsMojo shareholding |
Onkar Kanwar (individual promoter) | 0.01 | Mar 2026 | Shareholding pattern |
Total promoter & promoter group | 58.39 | Jun 2026 | Exchange filing |
International Finance Corporation (IFC) | 11.98 | Jun 2026 | MarketsMojo |
Total FIIs (21 FIIs, incl. IFC) | 12.29 | Jun 2026 | MarketsMojo |
Body corporate where Central/State Govt is promoter (name not disclosed in excerpt) | 1.90 | Mar 2026 | Shareholding pattern |
Mutual funds (5 schemes) | 1.30 | Jun 2026 | MarketsMojo |
Unclaimed suspense account | 1.48 | Mar 2026 | Shareholding pattern |
Individual investors | 12.79 | Jun 2026 | MarketsMojo |
Promoter shares pledged / encumbered | 44.53% of promoter holding | Jun 2026 | MarketsMojo; Screener |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Artemis | Relative positioning |
|---|---|---|
Medanta (Global Health Ltd) | Gurugram quaternary care — the most direct head-to-head competitor, located in the same city | Much larger; strong transplant/cardiac brand |
Fortis Healthcare (FMRI Gurugram, Fortis Escorts, Shalimar Bagh, Vasant Kunj etc.) | Gurugram and South/West Delhi high-acuity care; MVT | Larger network; FMRI is a direct Gurugram rival |
Max Healthcare Institute (Saket, Patparganj, Shalimar Bagh, Gurugram) | South Delhi (Saket) — key rival for VIMHANS catchment; MVT | Market leader in NCR by beds and ARPOB |
Apollo Hospitals Enterprise (Indraprastha Apollo, Sarita Vihar) | South Delhi tertiary care; MVT | National leader |
Manipal Hospitals (Dwarka, Gurugram) | West Delhi/Gurugram tertiary care | Large private network |
Paras Health (Gurugram) | Gurugram multi-specialty | Mid-sized regional player |
Narayana Health (Gurugram, Raipur MMI Narayana) | Gurugram presence and Raipur (MMI Narayana) — direct competitor for Artemis Shanti | Strong in Central/East India |
Ramkrishna CARE Hospitals / other Raipur tertiary hospitals; AIIMS Raipur (public) | Raipur catchment | Incumbents in Chhattisgarh |
Sir Ganga Ram, Indian Spinal Injuries Centre, BLK-Max | Delhi tertiary trust/private hospitals | Strong legacy brands |
Aster DM Healthcare, KIMS (Krishna Institute of Medical Sciences) | Capital-market peers; KIMS also collaborator | Listed peer benchmarks |
Peer Comparison FY2026
| Company | Market cap (INR Cr) | P/E (x) | Source / caveat |
|---|---|---|---|
Artemis Medicare | 4,958 | 43.6 | Mcap 12 Oct 2026 (Kotak Neo); P/E derived on TTM PAT INR 113.7 Cr |
Apollo Hospitals | 126,300 | 60.5 | Fyers peer table, date not stated |
Max Healthcare | 96,763 | 66.4 | Same |
Manipal Hospitals | 95,496 | 107.0 | Same |
Fortis Healthcare | 68,901 | 65.8 | Same |
Aster DM Healthcare | 68,592 | 215.2 | Same |
Narayana Health | 38,439 | 47.1 | Same |
Medanta (Global Health) | 38,149 | 68.6 | Same |
Recent Developments
Next expected event: board meeting to approve Q2 FY27 (quarter ended 30 Sep 2026) results — date not announced as of cut-off; prior-year Q2 was approved on 11 Nov 2025.



